Implementation Approaches in Heart Failure With Mildly Reduced and Preserved Ejection Fraction.

Competing Interests: Funding Support and Author Disclosures Dr Bhatt has received research grant support to his institution from the National Institutes of Health/National Heart, Lung, and Blood Institute, National Institutes of Health/National Institute on Aging, American College of Cardiology Foundation, and the Centers for Disease Control and Prevention; and consulting fees from Sanofi Pasteur and Novo Nordisk. Dr Filippatos has received research support from the European Union; reports lecture fees, advisory board, and/or committee member contributions in clinical trials sponsored by Bayer, Medtronic, Vifor, Servier, Novartis, Impulse Dynamics, Novo Nordisk, Cardior, and Boehringer Ingelheim. Dr Vaduganathan has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; and has participated on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics.